A Take-Private "Premium" Is a Discount in Disguise: Caesars, Integer, and Lantheus

Within one stretch of 2026, three familiar names agreed to stop being public companies: Caesars Entertainment, Integer Holdings, and Lantheus. Each deal waved a headline premium — 49% for Caesars, 51.8% for Integer, and up to 38% for Lantheus. The bulls read these as clean cash outs; the bears read them as buyers paying a premium to prices that were already discounted. Both camps are looking at the same numbers. What they disagree on is the measurement: a premium to where a stock traded is not the same thing as a price for what the business is worth. Which reading is right is exactly the question the word "fair" has to answer.

Shared facts. The three deals are not the same animal, so put them on a common card first.

Company	Buyer	Cash per share	Stated premium	What shareholders give up
Caesars (CZR)	Fertitta Entertainment	$31.00	49% to unaffected price	A leveraged regional casino business, net-income-negative
Integer (ITGR)	KKR	$127.00	51.8% to pre-review close	A steady medical-device contract manufacturer
Lantheus (LNTH)	Curium	$102.50 plus CVR up to $12 (up to $114.50)	21%–38% to May bases	A fast-growing radiodiagnostics franchise built on PYLARIFY

Caesars announced May 28 at $17.6 billion of enterprise value including roughly $11.9 billion of assumed debt. Integer and Lantheus both announced August 3, Integer at about $5.7 billion. Lantheus is worth up to about $8 billion.

The market's own math is already telling you how much each deal can be trusted. The stocks today sit at or just below their cash offers — that gap is the "merger arbitrage" spread, the market's estimate of deal risk and time-to-close. Integer trades less than a dollar below its $127 offer, near-total confidence. Lantheus trades about $2 below its $102.50 cash price, high but shaded by a closing in the first half of 2027. Caesars trades roughly $1.30 below its $31 offer — the widest of the three, a nod to the refinancing and regulatory work ahead. Those spreads measure whether each deal closes, not whether it is fair. Fairness is the harder question, and it has three rounds.

Round 1: A premium to what?

Every headline number above is anchored to a chosen base date, and the base does a lot of the work. Integer's 51.8% premium is measured against April 29 — the day before its board announced a strategic review. Announcing a review is another way of hanging a "for sale" sign over a stock; the review itself is what spooked the price, so the premium is partly recovering ground the company's own announcement took away. The same document concedes the offer is a smaller 28.8% premium to the 30-day average before the deal.

Caesars' 49% is measured to February 25, the last trading day before buyout rumors emerged — and before that, Caesars was not an ascendant stock; it was a highly levered name the market had already soured on. Lantheus' range of roughly 21% to 38% is measured against mid-May prices, before the approach from Curium leaked in the press.

So every buyer is paying a generous premium to the pre-rumor tape, and every buyer is also buying a company that had already been sold off, hung with a review, or leaked into the news. A low base inflates any percentage. That measurement win goes to the bears — but it's a scoring point, not the verdict. A premium to a depressed price still can be adequate compensation for a depressed asset.

Round 2: What the business is worth on its own

Now the fairness test shifts from arithmetic to economics, and the three companies stop looking alike.

Caesars is the clearest case for symmetry: it is a debt-heavy recovery story, not a compounding asset. It trades around five times EBITDA with a negative price-to-earnings ratio — the equity had been losing money. The buyer assumes the debt and hands shareholders a premium to step off a leveraged recovery that would have taken years of debt paydown to deliver. For that asset, a clean cash exit at a premium looks like a genuinely good outcome, the "business-bull, stock-bear" case where the stock's hope was a recovery the balance sheet made slow and uncertain.

Integer is the unglamorous median: a contract manufacturer for medical-device companies with low-single-digit revenue growth, an 18%-ish EBITDA margin, and a mid-teens EV/EBITDA multiple. It is a real, durable business — just not a rocket. The KKR offer is all cash, with no financing condition, and follows a board process that consulted advisors on a range of alternatives.

Lantheus is the outlier, and it is the reason this story has tension. It makes PYLARIFY, the PSMA PET imaging agent that reshaped prostate-cancer imaging, and it has behaved like a growth stock: shares up roughly 90% over the past year, high double-digit operating and free-cash-flow margins, profitability that its buyers lack, trading near 21 times forward earnings. In the shared-facts card, Lantheus is the only company whose shareholders are being asked to give up a compounding franchise rather than a stale or troubled one. The economics round also goes to the bears, and by a wider margin on Lantheus.

Round 3: What you get now vs. what the buyer keeps

This is where the fairness question actually gets decided, and it is why Lantheus is the weakest of the three. The headline "$102.50 plus a CVR worth up to $12," for a total up to $114.50, reads as a range with upside. But the contingent value right is not a share of future success — it is a capped, non-transferable payment tied to specific sales hurdles. The CVR pays out only if global prostate-cancer diagnostic sales (think PYLARIFY) clear thresholds running from $950 million up to $1.75 billion by fiscal 2030, with separate milestones for the neurology imaging agent Neuraceq and the DEFINITY ultrasound business. Whatever PYLARIFY produces above the top rung belongs to the buyer, not to the shareholder who helped build it.

The bull's best answer is legitimate: $102.50 of cash is real and immediate, certainty has value, and a business that leans on one flagship product carries single-product risk that a cash exit removes. All of that is true. But the structure is doing the emotional work of making a modest base look generous. A shareholder who believed PYLARIFY would keep compounding is asked to swap the franchise for a fixed amount plus a lottery ticket that pays only on a backdated schedule, with the ceiling kept by the buyer. That is the defining giveaway of the whole group.

Ruling: who got a fair price?

Fairness has to be judged per company, and the evidence ranks them rather than ranking them equal.

Integer's deal is the cleanest fair price. A 51.8% premium to the pre-review close, all cash, no financing contingency, a genuine board process — and the market prices near-total confidence that it closes. Shareholders are surrendering a steady, unexciting company and getting paid well in relation to what it was about to trade at. The burden for calling it unfair would rest with anyone betting Integer re-rates as a standalone compounder, and single-digit growth makes that a weak wager.

Caesars' exit is fair-to-reasonable. For a leveraged, loss-making recovery asset, taking a 49% cash premium off a depressed base is not being shortchanged; it is being paid to exit a bet that needed years and refinancing to pay off. The wide arbitrage spread is about the closing mechanics, not the price.

Lantheus is the weak link. The stated premium is the lowest of the three relative to what the owner is giving up, and the highest-quality asset. The "up to" CVR gives the deal the appearance of a generous range while capping the very compounding the buyer is paying for. Shareholders here are not clearly getting a fair price for the franchise; they are getting a fair price for the stock, plus a backdated, capped contingency.

The ruling on Lantheus flips if the evidence before closing says the CVR is set too low — if PYLARIFY momentum makes the 2030 milestones look easily reachable, the offer tilts from merely conservative toward cheap. That is the tripwire to watch around the October 14 shareholder vote: not just whether it passes, but whether prostate-diagnostics sales are tracking ahead of the thresholds the CVR rewards. And the takeaway that travels beyond these three names is simpler: when a buyer offers a capped contingent payment, discount it hard. A capped "up to" is the buyer telling you they expect the ceiling, not the runway — and a fair deal priced off a depressed stock can still be the cheapest thing a leveraged or growth-hungry buyer buys all year.